Pharming Group NV said that it expects the US Food and Drug Administration to complete its review, or otherwise respond, to its biologics licence application for Ruconest (recombinant human C1 esterase inhibitor) by 16 April 2014. ---Subscribe to MedNous to access this article--- Company News
